WE ARE GATEHOUSE BIO

We believe there is an RNA code that drives every disease
  • Our mission is to find that code and use it to develop effective therapeutics
  • Our Code-Breaker™ platform uses AI to decode the landscape of small RNAs (sRNAs) and digitally design biomarker-guided precision oligonucleotide therapeutics
  • We are currently developing our lead targets into therapies to treat pulmonary, cardiac, neurological, and autoimmune diseases
With every single code we break, we unlock the potential to improve the lives of many

To learn more about our company and the potential of sRNA in precision medicine

Contact Us

research Collaborations

We are seeking researchers that who are discovering biomarkers, hunting for novel drug targets or exploring disease to better understand biology.

Contact us to learn more about sRNA and Code-Breaker™.

Business Development

It takes an ecosystem of interdisciplinary experts to bring new precision medicines from discovery to the clinic. We are seeking partners to co-develop precision medicines and integrate Code-Breaker into their discovery pipeline. Our data has demonstrated application across multiple therapeutic areas.

Contact us to learn more.

Investors

The future of precision sRNA medicine will be realized through continued use of Code-Breaker to learn and predict complex mRNA :: sRNA activity relationships and design therapeutics. Our next major milestone is to bring our first lead through human clinical trials; we will accomplish this goal with an ecosystem that we have been developing over the last 4 years. We are seeking investors to help expand our potential.

Contact us to learn more about our traction and plans.

Contact Us

Thanks for your interest! Please fill out the form below to download a copy of our case study

David Salzman, PhD

As founder and CEO of Gatehouse Bio, David has over 14 years of research expertise and experience in microRNA and sRNA biology. He is the force behind the science and technological development required for identifying sRNA diagnostics, targeted assay design, validation, and subsequent product development. He was previously a postdoctoral fellow at the Yale School of Medicine and a scientist at Biogen, where he gained experience in developing clinical and preclinincal biomarker, PK/PD, and diagnostic platforms. David also served as the CSO of MiraDx, spearheading projects to commercialize germline DNA biomarkers in oncology. He earned his PhD in Molecular Biology and Biochemistry from the University of Connecticut and a BS in Environmental Science from the University of Hartford.


View his publication record here.

If you have any questions or would like to set up a call to talk about a future partnership, we would love to hear from you. Please fill out the form below and one of our members will be in touch.